A Study to Assess the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes in Healthy Adult Participants
Completed · Phase 1 · NCT06571266
Conditions: Healthy Volunteers
At a glance
- Research payments reported, 2025
- $2.6M
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 231
About the trial
- Sponsor
- AbbVie
- Tested
- Risankizumab (drug)
- Dates
- Started 2024-09-11; completion 2025-04-16
- Results posted
- Not yet
This study will assess the pharmacokinetics, relative bioavailability and tolerability of two formulations of risankizumab following subcutaneous (SC) administration in healthy adult participants.
From ClinicalTrials.gov, last updated 2025-05-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $2.6M in research payments for this study in 2025 (31 payments).
Products named: Skyrizi
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Steven H. Reynolds, D.O. Family Medicine · Long Beach, CA
- Peter J. Winkle, MD Gastroenterology · Cypress, CA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Cenexel Clinical Research Inc $1.3M
- Anaheim Clinical Trials LLC $1.3M
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.